Literature DB >> 20841491

Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis.

Cornelia Bigler1, Helmut Hopfer, Doris Danner, Monica Schaller, Michael J Mihatsch, Marten Trendelenburg.   

Abstract

BACKGROUND: In systemic lupus erythematosus patients, a strong association between the occurrence of antibodies against complement C1q (anti-C1q) and lupus nephritis can be observed. However, the predictive value of anti-C1q titres for a renal flare remains to be determined. Increasing titres of anti-C1q before the occurrence of clinical apparent nephritis might not only serve as a clinical parameter but also indicate a direct pathogenic mechanism of anti-C1q.
METHODS: The aim of this study was to analyse the occurrence of anti-C1q before the onset of experimental lupus nephritis in MRL/MpJ +/+ mice and to correlate anti-C1q titres with the type and severity of glomerulonephritis (GN) developing at advanced age.
RESULTS: As judged by a number of morphological and immunological analyses, GN in MRL/MpJ +/+ mice resembled human lupus nephritis and occurred in variable degrees of severity. We also observed an abundant and early presence of anti-C1q. However, anti-C1q neither correlated with overall survival nor with any histological marker of severity of GN.
CONCLUSIONS: The absence of a correlation between the presence of anti-C1q and the occurrence of experimental lupus nephritis contradicts the hypothesis that anti-C1q are pathogenic. However, different pathogenic mechanisms of experimental lupus nephritis and human proliferative lupus nephritis cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20841491     DOI: 10.1093/ndt/gfq558

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis.

Authors:  Nicola Bassi; Dorella Del Prete; Anna Ghirardello; Mariele Gatto; Monica Ceol; Margherita Zen; Silvano Bettio; Alberto Mantovani; Luca Iaccarino; Leonardo Punzi; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

2.  C1q as a target molecule to treat human disease: What do mouse studies teach us?

Authors:  Kristina Schulz; Marten Trendelenburg
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

3.  Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes.

Authors:  Izeta Aganovic-Musinovic; Jasenko Karamehic; Lamija Zecevic; Faris Gavrankapetanovic; Nesina Avdagic; Asija Zaciragic; Tomislav Jukic; Nerima Grcic; Suvada Svrakic
Journal:  Autoimmune Dis       Date:  2012-10-11

4.  Role of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE.

Authors:  Mohamed Salah Eldin Mohamed Abdel Kader; Mohamed Momtaz Abd Elaziz; Dina Hisham Ahmed
Journal:  Expert Opin Med Diagn       Date:  2012-08-15

5.  Anti-C1q autoantibodies, novel tests, and clinical consequences.

Authors:  Michael Mahler; Rosanne A van Schaarenburg; Leendert A Trouw
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.